SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price cut by analysts at Piper Sandler from $24.00 to $14.00 in a research note issued on Thursday,Benzinga reports. The brokerage ...

The study found that Prequel ® Prenatal Screen with AMPLIFY™ technology enables reliable results as early as eight-weeks’ gestation. Typically, prenatal cell-free DNA (pcfDNA) screening is offered ...

Piper Sandler analyst David Westenberg lowered the firm’s price target on Myriad Genetics (MYGN) to $14 from $24 and keeps a Neutral rating on ...

Myriad Genetics, Inc. has launched a new educational website called "Know More Sooner," aimed at providing detailed information about reproductive and prenatal genetic testing. The site seeks to ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 3.75% of ...

SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, has launched a new educational website providing ...

SALT LAKE CITY, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it will unveil groundbreaking research ...

Myriad Genetics, Inc. is headquartered in Salt Lake City, UT. The company is focused on developing, producing and distributing genetic tests utilized in the oncology and women's and ...